Want to see WGRX full AI Analyst Report?
WGRX Stock Chart & Stats
$0.14
--
Market closed
$0.14
--
Day’s Range― - ―
52-Week Range$2.48 - $97.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)28.82M
Market Cap
$7.92M
Enterprise Value$38.16M
Total Cash (Recent Filing)$51.73K
Total Debt (Recent Filing)$28.91M
Price to Earnings (P/E)―
Beta0.72
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,647,198
10 Day Avg. Volume1,367,507
30 Day Avg. Volume28,820,997
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.28
Price to Sales (P/S)1.22
P/FCF Ratio-2.61
Enterprise Value/Market Cap4.82
Enterprise Value/Revenue2.72
Enterprise Value/Gross Profit-3.93
Enterprise Value/Ebitda-0.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Rebranding To DataMeds AI And Strategic PivotThe rebrand and stated strategy signal a structural shift toward vertically integrated AI and blockchain healthcare data services. By expanding EinsteinRx and PharmacyChain and targeting patient-controlled data, the company aims to build long-term data assets and platform stickiness that can create recurring revenue and differentiation if execution follows plan.
Recent Convertible Financing Improved Near-term RunwayThe private financing materially extended liquidity and reduced immediate creditor pressure, allowing management to execute strategic transactions and stabilize operations. While convertible instruments carry future dilution risk, the cash proceeds and partial debt repayment provide tangible runway to pursue integration of acquisitions and product development.
Operational Traction And Strategic PartnershipsSequential revenue gains and a much smaller quarterly operating loss show initial progress from the pivot to direct-to-consumer channels and telepharmacy JV access to ~200k patient lives. Partnerships (Kare Pharmtech, Tollo Health, NFL Alumni Health) create distribution and data feed opportunities that can support sustainable revenue growth as the platform scales.
Bears Say
Severe Profitability Deterioration And Cash BurnDeeply negative gross and net margins indicate core unit economics are currently unviable: the company is losing money at the operational level and burning cash. Persistent negative operating cash flow requires repeated external funding, weakening long-term self-sufficiency and increasing the likelihood that future strategy depends on dilutive financing or asset sales.
Negative Equity And Elevated LeverageNegative book equity and meaningful indebtedness constrain financial flexibility, limit access to traditional capital markets, and raise refinancing and solvency risks. This structural weakness heightens vulnerability to covenant breaches and listing non-compliance, making sustained investment in product development or go-to-market initiatives more difficult without continued external support.
Potential Major Dilution And Governance Change From Proposed DealA transaction that awards near-total post-conversion equity to counterparties implies material shareholder dilution and a likely shift in control and strategy. Such a structural change could undermine incumbent shareholder interests, alter priorities, and impose execution risk as new owners integrate assets and restructure operations, affecting continuity and long-term value.
Wellgistics Health Inc News
WGRX FAQ
What was Wellgistics Health Inc’s price range in the past 12 months?
Wellgistics Health Inc lowest stock price was $2.48 and its highest was $97.50 in the past 12 months.
What is Wellgistics Health Inc’s market cap?
Wellgistics Health Inc’s market cap is $7.92M.
When is Wellgistics Health Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Wellgistics Health Inc’s earnings last quarter?
Currently, no data Available
Is Wellgistics Health Inc overvalued?
According to Wall Street analysts Wellgistics Health Inc’s price is currently Overvalued.
Does Wellgistics Health Inc pay dividends?
Wellgistics Health Inc does not currently pay dividends.
What is Wellgistics Health Inc’s EPS estimate?
Wellgistics Health Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wellgistics Health Inc have?
Wellgistics Health Inc has 2,647,198 shares outstanding.
What happened to Wellgistics Health Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Wellgistics Health Inc?
Currently, no hedge funds are holding shares in WGRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wellgistics Health Inc
Wellgistics Health, Inc. functions as a primary wholesaler and distributor of pharmaceutical products throughout the United States, catering to both drug manufacturers and independent retail pharmacies. Its extensive product catalog includes a variety of generic and brand-name pharmaceuticals, alongside over-the-counter healthcare and consumer merchandise. The company also delivers a suite of third-party logistics (3PL) services, encompassing warehousing, inventory control, pick-and-pack operations, and shipping solutions, specifically designed for small to mid-sized pharmaceutical producers. Furthermore, Wellgistics manages the DelivMeds platform, an integrated pharmaceutical hub that streamlines prescription transfers and offers essential backend clinical concierge support to its network of independent pharmacies. It also runs a specialized retail community service. Established in 2022 and headquartered in Tampa, Florida, the organization adopted its current name, Wellgistics Health, Inc., in October 2024, having previously operated as Danam Health, Inc.
Technical Analysis
―
Prestige Consumer Healthcare
―
―
Synergy CHC
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
20.40% Insiders
17.09% Mutual Funds
― Other Institutional Investors
62.09% Public Companies and
Individual Investors